# Hikma Pharmaceuticals Plc 22.2% potential upside indicated by RBC Capital Markets

- Link: https://www.directorstalkinterviews.com/hikma-pharmaceuticals-plc-22.2-potential-upside-indicated-by-rbc-capital-markets/4121133793
- Published: 2023-11-22T12:58:53+00:00
- Author: Charlotte Edwards

**[Hikma Pharmaceuticals Plc](https://www.directorstalkinterviews.com/ftse-company/hikma-pharmaceuticals/hik.l)**
with ticker (LON:HIK) now has a potential upside of 22.2% according to RBC Capital
Markets.
RBC Capital Markets set a target price of 2,150 GBX for the company, which
when compared to the Hikma Pharmaceuticals Plc share price of 1,759 GBX at opening
today (22/11/2023) indicates a potential upside of 22.2%. Trading has ranged between
1,418 (52 week low) and 2,222 (52 week high) with an average of 461,882 shares exchanging
hands daily. The market capitalisation at the time of writing is £3,885,466,940.
Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities
are the development, manufacturing, marketing and selling of a range of generic,
branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and
injectable final dosage forms. The Company operates through three segments: Injectables,
Generics and Branded. Injectables segment supply hospitals across its markets with
generic injectables, supported by its manufacturing facilities in the United States,
Europe and Middle East/North Africa (MENA). Generics segment supply oral and other
non-injectable generic and specialty branded products in the United States retail
market. Branded segment supply branded generics and in-licensed patented products
in MENA. It also markets its products in Canada and, which includes approximately
25 sterile injectable products, three in-licensed ophthalmic products and a pipeline
of seven additional products.

Share on: